Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer
Shannon Puhalla, Adam BrufskyUPMC Magee-Womens Cancer Program, University of Pittsburgh, Pittsburgh, Pennsylvania, USAAbstract: Taxane therapy is commonly used in the treatment of metastatic breast cancer. However, most patients will eventually become refractory to these agents. Ixabepilone is a new...
Saved in:
Main Authors: | Shannon Puhalla, Adam Brufsky |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2008
|
Subjects: | |
Online Access: | https://doaj.org/article/4209a5255f9042edac6dae63e7d778f0 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bevacizumab in the therapy for refractory metastatic colorectal cancer
by: Mary F Mulcahy
Published: (2008) -
Eribulin mesylate in the treatment of metastatic breast cancer
by: Jain S, et al.
Published: (2012) -
Current neoadjuvant treatment options for HER2 positive breast cancer
by: Abdel-Razeq H, et al.
Published: (2011) -
Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis.
by: Lixian Zhong, et al.
Published: (2013) -
Metastatic and locally aggressive BCC: Current treatment options
by: Máire‐Caitlín Casey, et al.
Published: (2021)